Isolation of Streptomyces sp. KK65 as a produceer of β-amyloid aggregation inhibitor

Journal of Microbiology and Biotechnology

Volumn 13, Issue 5, 2003, Pages 809-814

  Hwang, Sung Eun ^a   Im, Hyung Min ^d   Kim, Dong Hoon ^a   Shin, Hyun Ju ^d   Shin, Dong Hoon ^a   Park, Jeong Eun ^d   Jo, Inho ^d   Kim, Chang Jin ^b   Yoo, Jong Shin ^c   Kang, Jong Min ^a   Lim, Dong Yeol ^a   Jo, Sangmee Ahn ^d   Kwon, Ho Jeong ^a  

^a Sejong University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Korea Basic Science Institute (KBSI)   (South Korea)

^d Korea National Institute of Health   (South Korea)

Author keywords

amyloid; A aggregation inhibitor; Alzheimer's disease; Streptomyces sp.

Indexed keywords

AMYLOID BETA PROTEIN; CELL EXTRACT; CONGO RED; DIAMINOPIMELIC ACID; PROTEIN ANTIBODY; PROTEIN INHIBITOR; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; CELL WALL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; FUNGAL CELL; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; MICROBIAL METABOLISM; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN STABILITY; SOIL MICROFLORA; STRAIN IDENTIFICATION; STREPTOMYCES;

FUNGI; STREPTOMYCES; STREPTOMYCES SP.;

EID: 0242551359     PISSN: 10177825     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Eckman, E. A., D. K. Reed, and C. B. Eckman. 2001. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 27: 24540-24548.
2. Geula, C., C. Wu, L. Saroff, M. Yuan, and B. Tankner. 1998. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat. Med. 4: 827-831.
3. Glenner, G. G. and C. W. Wong. 1984. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochim. Biophys. Res. Commun. 120: 885-890.
4. Hasse, C. and D. J. Selkoe. 1993. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell 75: 1039-1042.
5. Iwata, N., S. Tsubuki, Y. Takaki, K. Shirotani, B. Lu, N. P. Gerard, C. Gerard, E. Hama, H. J. Lee, and T. C. Saido. 2001. Metabolic regulation of brain Aβ by neprilysin. Science 292: 1550-1552.
6. Iwata, N., S. Tsubuki, Y. Takaki, K. Watanabe, M. Sekiguchi, E. Hosoki, M. Kawashima-Morishima, H. J. Lee, E. Hama, Y. Sekine-Aizawa, and T. C. Saido. 2000. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat. Med. 6: 718-719.
7. Klunk, W. E., J. W. Pettegrew, and D. J. Abraham. 1989. Quantitative evaluation of Congo red binding to amyloid-like proteins with a β-pleated sheet conformation. J. Histochem. Cytochem. 37: 1273-1281.
8. Kwon, H. J., S. E. Hwang, J. T. Han, C. J. Kim, J-R. Rho, and J. Shin. 2001. Production of olemiade, functional lipid, by Streptomyces sp. KK90378. J. Microbiol. Biotechnol. 11: 1018-1023.
9. Kwon, H. J., D. H. Kim, J. S. Shim, and J. W. Ahn. 2002. Apicularen A, a macrolide from Chondromyces sp. inhibits growth factor induced in vitro angiogenesis. J. Microbiol. Biotechnol. 12: 702-705.
10. LeVine, H. 1993. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2: 404-410.
11. Mosman, T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.
12. Schenk, D., R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Motter, F. Soriano, G. Shopp, N. Vasquez, C. S. Vendevert, M. Wogulis, T. Yednock, D. Games, and P. Suebert. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
13. Schroeter, E. H., J. A. Kisslinger, and R. Kopan. 1989. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393: 382-386.
14. Selkoe, D. J. 1994. Alzheimer's disease: A central role for amyloid. J. Neuropathol. Exp. Neurol. 53: 438-447.
15. Selkoe, D. J. 2001. Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81: 741-766.
16. Vandermeeren, M., M. Geraerts, S. Pype, L. Dillen, C. Van Hove, and M. Mercken. 2001. The functional gamma-secretase inhibitor prevents production of amyloid β 1-34 in human and murine cell lines. Neurosci. Lett. 27: 145-148.
17. Yankner, B. A., L. K. Duffy, and D. A. Kirschner. 1990. Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides. Science 250: 279-282.
18. Yasojima, K., H. Akiyama, E. G. McGeer, and P. L. McGeer. 2001. Reduced neprilysin in high plaque areas of Alzheimer brain: A possible relationship to deficient degradation of β-amyloid peptide. Neurosci. Lett. 12: 97-100.
19. Yoshiike, Y., K. Tanemura, O. Murayama, T. Akagi, M. Murayama, S. Sato, X. Sun, N. Tanaka, and A. Takashima. 2001. New insights on how metals disrupt amyloid β-aggregation and their effects on amyloid-β cytotoxicity. J. Biol. Chem. 276: 32293-32299.
20. Zhu, Y. J., H. Lin, and R. Lal. 2000. Fresh and nonfibrillar amyloid β protein (1-40) induces rapid cellular degeneration in aged human fibroblasts: Evidence for AbetaP-channel-mediated cellular toxicity. FASEB J. 14: 1244-1254.